About this trial
These two drugs are already used to treat patients with prostate cancer.
Xofigo® contains the radioactive substance radium-223 which mimics the calcium found in bones. When injected into a patient, radium-223 reaches the bone where the cancer has spread to and emits short-range radiation (alpha particles) which kills the surrounding tumor cells.
Xtandi® is an antiandrogen cancer medicine. It works by blocking the effects of androgen (a male hormone) to stop the growth of prostate cancer cells.
Participants will be split into two groups. Each group will receive a different treatment. The treatment each group receives is determined by chance using a computer program.
In group 1 patient will receive Xofigo® combined with Xtandi® which is considered the ‘experimental’ treatment. In group 2 patient will receive Xtandi® alone.
asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone
Where’s this trial being run?
Cork University Hospital, St Luke’s Radiation Oncology Network @ St Luke’s Hospital, Tallaght University Hospital, and St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Here’s a list of questions you may have for your doctor or local cancer research team.Questions
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
|Principal Investigator:||Prof Ray McDermott (Tallaght University Hospital)|
European Organisation for Research and Treatment of Cancer – EORTC
Global: October 2015
Ireland: April 2019
|Global Recruitment Target:||560|
|Ireland Recruitment Target:||60|